International Meeting dedicated to the memory of Raisa Gorbacheva. HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007

Similar documents
4nd Patient and Family Day

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

Hematopoetic Stem Cell Therapies in TURKIYE

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

Recommended Timing for Transplant Consultation

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

Clinical Policy: Donor Lymphocyte Infusion

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Stem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP

An Introduction to Bone Marrow Transplant

Bone Marrow Transplantation and the Potential Role of Iomab-B

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Regence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER

Leukine. Leukine (sargramostim) Description

Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation. December Reference : NHSCB/B4/a/1

Dr.PSRK.Sastry MD, ECMO

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

What are stem cells? A stem cell can differentiate into any one of 220 different specialised cells in the body STEM CELLS

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

An Overview of Blood and Marrow Transplantation

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

Blood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen

What s a Transplant? What s not?

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines

Il Trapianto da donatore MUD. Alessandro Rambaldi

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

Introduction to Hematopoietic Stem Cell Transplantation

Leukine. Leukine (sargramostim) Description

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014

Reduced-intensity Conditioning Transplantation

Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

The Immunobiology Working Party

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

Myeloproliferative Disorders - D Savage - 9 Jan 2002

Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation. Disclosure of Interest: Nothing to Disclose

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

FILE - STEM CELL TRANSPLANT FOR MDS ARCHIVE

DEPARTMENT OF CLINICAL HEMATOLOGY

HAEMATOPOIETIC STEM CELL TRANSPLANTATION

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -

Dedicated to Gordon. Stem Cell Transplantation: The Journey

Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale

Stem Cell Transplantation for Severe Aplastic Anemia

Stem Cell Transplantation

Haplo vs Cord vs URD Debate

Le infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy

Corporate Medical Policy

The Role of Conventional Donor Lymphocyte Transfusions. Hans-Jochem Kolb 3rd Med. Dept. Klinikum re der Isar Technische Universitaet Muenchen Germany

Company Overview. January 2019

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

Therapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.

Disclosures of: Emanuele Angelucci

Hematopoietic Stem Cells

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s

AIH, Marseille 30/09/06

Haploidentical Transplantation today: and the alternatives

Review of Stem Cell Collection Data 2016 Ronan Foley, Professor, Director Stem Cell Laboratory, McMaster University

16:00 17:15 hrs - Session 1 - Rare diseases and new approaches. Chair: Alexander Claviez (Kiel), Krzysztof Kalwak (Wroclaw)

COHEM Barcellona 2012 Hemoglobinopathies debate

Leukine. Leukine (sargramostim) Description

Corporate Medical Policy

The question is not whether or not to deplete T-cells, but how to deplete which T-cells

Clinical Policy: Donor Lymphocyte Infusion Reference Number: CP.MP.101 Last Review Date: 11/17

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

HCT for Myelofibrosis

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

THE LEUKEMIAS. Etiology:

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

Index. Note: Page numbers of article titles are in boldface type.

T cell manipulation of the graft: Yes

Causes of Death. J. Douglas Rizzo, MD MS February, New11_1.ppt

Haematopoietic stem cell transplantation (SCT)

Blood & Marrow Transplantation Center

EBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda

Transcription:

International Meeting dedicated to the memory of Raisa Gorbacheva HEMOPOIETIC STEM CELLS TRANSPLANTATION Saint-Petersburg, September 21-22, 2007 Preliminary program September 21 Friday 8.00-8.30 - registration of participants 8.30-9.00 - opening speech Yaitsky Nikolay (Russian Federation) Zander Axel (Germany) Buchner Thomas (Germany) Wisloff Finn (Norway) Friedrichs Martin (Germany) Roumiantsev Alexander (Russian Federation) Afanasyev Boris (Russian Federation) Session 1 9.00-11.50 Pediatric session Chair persons: Dini Giorgio, Roberts Irene, Roumiantsev Alexander 9.00-9.30 Buchner Thomas (Germany) Raisa Gorbacheva Memorial Lecture Treatment of acute myeloid leukemia: present status and new directions 9.30-10.00 Willem Fibbe Alexander Fridenshtein Memorial Lecture The mesenchymal paradigm 10.00-10.20 Dini Giorgio (Italy) Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the pediatric diseases working party of the European Group for Blood and Marrow Transplantation 10.20-10.35 Roumiantsev Alexander (Russian Federation) HSCT in children with Aplastic Anemia

10.35-10.55 Roberts Irene (United Kingdom) BMT for haemoglobinopathies 10.55-11.10 Fechina Larisa (Russian Federation) New insight in treatment of inborn leukemia 11.10-11.25 Aleinikova Olga (Belorussia) Current status hematopoietic stem cell transplantation in children in Belarussia 11.25-11.40 Mentkevich Georgij (Russian Federation) Non-T-depleted HLA haploidentical stem cell transplantation in children with advanced malignancies 11.40-11.50 Semenova Elena (Russian Federation) HSCT in patients with genetic and inherited diseases 11.50-12.10 Coffee break Session 2 12.10-14.10 Haemopoietic Stem Cell Transplantation Chair persons: Zander Axel, Huang Xiaojun, Savchenko Veleriy 12.10-12.40 Zander Axel (Germany) Reduced-intencity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis 12.40-13.00 Huang Xiaojun (China) Haploidentical HSCT. 13.00-13.20 Tangen Jon Magnus (Norway) Survival in Norwegian patients with acute myelogenous leukemia receiving allogeneic stem cell transplantation in first remission. A report from the Norwegian Acute Leukemia Registry 13.20-13.40

Savchenko Veleriy (Russian Federation) Monitoring of minimal residual disease in patients with hemoblastosis during polychemotherapy and after bone marrow transplantation 13.40-13.55 Blau Igor (Germany) Comparison of allogeneic HSCT after reduced intensity versus conventional conditioning 13.55-14.10 Delioukina Maria (USA) Novel conditioning regimen for allogeneic stem cell transplantation 14.10-14.20 Demidova Irina (Russian Federation) Allogenic Bone Marrow Transplantation with RIC in patients with hemoblastosis 14.20-15.10 Lunch Session 3 15.10-16.30 Haemopoietic Stem Cell Transplantation Chair persons: Andreeff Michael, Kolb Hans-Jochem, Tangen Jon Magnus 15.10-15.40 Kolb Hans-Jochem (Germany) Strategies of immunotherapy in chimerism 15.40-16.10 Ferrara James (USA) A new approach to clinical GVHD: Cytokline Inhibition 16.10-16.25 Afanasyev Boris (Russian Federation) Single Centre experience in the field of HSCT 16.25-16.45 Fossum Sigbjørn (Norway) Natural Killer cells in GvHD 16.45-17.05

Coffee break Session 4 17.05-18.30 Haemopoietic Stem Cell Transplantation Chair persons: Wisloff Finn Muller-Hermelink Hans-Konrad, Novik Andrey, 17.05-17.25 Muller-Hermelink Hans-Konrad (Germany) The biology of peripheral T cell Lymphomas - Is HSTCT a treatment option 17.25-17.45 Wisloff Finn (Norway) Quality of Life in autologous stem cell transplantation in multiple Myeloma 17.45-18.00 Novik Andrey (Russian Federation) HSCT in patients with multiple sclerosis 18.00-18.10 Klimko Nikolaj (Russian Federation) Systemic Fungal Infection after Chemotherapy and Hematopoietic Stem Cell Transplantation in Children and Adults 18.10-18.25 Ptushkin Vadim (Russian Federation) Mobilization of peripheral blood stem cell by granulocytic colony- stimulating growth factor "Leukostim" (BioKad) Social events

September 22 Saturday Session 5 9.00-11.15 Stem Cell Research Chair persons: Borset Magne, Fibbe Willem, Westenfelder Christof 9.00-9.30 Wagemaker Gerard (Netherlands) Hematopoietic stem cells as targets for gene therapy of inherited diseases 9.30-9.50 Westenfelder Christof (USA) Protective and regenerative actions of administered, bone marrow-derived, multipotent stromal cells (MSC) in acute kidney injury (AKI): relevance to clinical trials 9.50-10.10 Lange Claudia (Germany) Gene expression profile reflects accelerated growth and improved immunimmodulatory properties of plated lysate-generated mesenchymal stromal cells 10.10-10.30 Andreeff Michael (USA) Mesenchymal Stroma Cells (MSC) Selectively Produce Targeted Anti-Cancer Agents in the Tumor Microenvironment 10.30-10.45 Egeland Torstein (Norway) Stem cell differentiation into neurons - potential clinical usage 10.45-11.05 Borset Magne (Norway) Impediment of mesenchymal stem cell differentiation - consequence for the bone disease in multiple Myeloma 11.05-11.15

Blau Olga (Germany) Genetic aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrom and acute myeloid leukemia 11.15-11.25 Nemkov Alexander (Russian Federation) Usage of bone marrow mononuclear cells in patients with heart disease 11.25-11.35 Coffee break Session 6 11.35-13.20 Donor s registries Chair persons: Egeland Torstein, Koza Vladimir, Morsch Emil 11.35-12.05 Egeland Torstein (Norway) HLA-typing 12.05-12.25 Koza Vladimir (Czech Republic) The impact of non-hla attributes on outcome of unrelated donors stem cell transplantation 12.25-12.40 Dini Giorgio (Italy) The strategy of the search for children lacking a MSD (UD SCT, CB SCT, Haplo-SCT) 12.40-12.55 Morsch Susanne (Germany) The Donor Search Process 12.55-13.05 Alyanskiy Alexander (Russia) Initiation of donor search for patients of SPMU BMT Clinic 13.05-13.20 Bubnova Ludmila (Russia) Service of immunology tissue typing and stem cell donor registry in Russia today 13.20-14.20

Lunch Session 7 14.20-16.05 Miscellanies Chair persons: Everaus Hele, Harousseau Jean-Luc, Palutke Margarita 14.20-14.40 Harousseau Jean-Luc (France) Current status of autologous stem cell transplantation in Multiple Myeloma 14.40-15.00 Palutke Margarita (USA) Clonal B Lymphocytic Proliferations in Myelodysplasia and Myeloid Leukemias May Point to a Common - B Cell - Myeloid - Stem Cell 15.00-15.15 Lisukov Igor (Russian Federation) High dose immune therapy and hematopoietic stem cells transplantation in patients with autoimmune diseases 15.15-15.35 Lioznov Mikhail (Germany) Aldehyde dehydrogenase activity as a marker for normal and leukemic haematopoietic stem cells 15.35-15.45 Babenko Elena 15.45-16.00 Lobzin Yriy Experience of long-term cryogenic bone marrow storage 16.00-16.20 Rascon Jelena (Lithuania)

Chimerism analysis after allogeneic HSCT 16.20-16.40 Coffee break Session 8 16.40-18.00 Miscellanies Chair persons: Fehse Boris, Fossum Sigbjørn, Wagemaker Gerard 16.40-17.00 Fehse Boris (Germany) Retroviral gene transfer in haematopoietic stem cell transplantation models 17.00-17.20 Everaus Hele (Estonia) Connection of haemopoietic stem cells with other possible celltherapy options 17.20-17.35 Balaian Larissa (USA) CD33 targeted treatment of AML 17.35-17.50 Roumiantsev Sergej (Russian Federation) Cord blood as a source of unrelated HSCT for children 17.50-18.05 Konopleva Marina (USA) Stroma interactions and CXCR4 signaling Poster awards Kolb Hans-Johem (Germany) Palutke Margarita (USA) Savchenko Veleriy (Russian Federation) Closing remarks Roumiantsev Alexander (Russian Federation) Zander Axel (Germany) Afanasyev Boris (Russian Federation)

Social events